Atacand to take on Novartis' Diovan
New drug receives two licences
Company aligns salesforce to PCO boundaries
Yale researchers say trial may be flawed
Improvement Plan pledges made
Autonomous regional account managers planned
Ten more NHS trusts approved
Trial disappointing for Novartis
Poll results support re-importation
Merged company offers global services